Press releases

A live webcast and replay of the July 26 conference call will be available.

"Patient safety continues to be our highest priority," said Jim Tobin, President and Chief Executive Officer.

Prospective, multi-center, randomized study designed to evaluate the benefits of filter-based embolic protection during primary percutaneous coronary intervention (PCI) in acute myocardial infarction (AMI).

The voluntary recall does not affect patients who have already received a TAXUS stent.

Company plans to use the proceeds to repay commercial paper borrowings and for other general corporate purposes.

Company announces launch of a public offering of $500 million aggregate principal amount of senior notes.

A live webcast and replay of the June 9th conference session will be available.

Company estimates that its share of the U.S. drug-eluting stent market - as of May 31st - continues to be in excess of 70 percent, on a reorder basis.

Acquisition will bring neuromodulation technology, including a range of neurostimulators, programmable drug pumps and cochlear implants.

(May 28, 2004) -- Boston Scientific Corporation (NYSE: BSX) announced today that the U.S. Court of Appeals for the Federal Circuit has affirmed a decision by the U.S. District Court in Wilmington,...